Spero Therapeutics, Inc. (SPRO): Valuation
TTM figures as of June 30, 2026
Spero Therapeutics, Inc. trades at 8.9 times trailing earnings. On P/E that is higher than 48% of its own month-end history back to 2017. The Healthcare median P/E is 22.9.
Earnings yield 11.22%.
106 month-end valuation observations are on file, starting November 2017.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is SPRO cheap versus its own history?
Spero Therapeutics, Inc. trades at 8.9 times trailing earnings. On P/E that is higher than 48% of its own month-end history back to 2017. The Healthcare median P/E is 22.9.
What is SPRO's free-cash-flow yield?
Free-cash-flow yield is trailing free cash flow divided by the live market cap. It is omitted when free cash flow is missing.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.